Browsing tag:

Antidepressant


Levomilnacipran, CAS number 96847-55-1, has been a headline in the recent pharmaceutical news. This headline status is due to the FDA approval of Fetzima, the brand name for Levomilnacipran, at the end of July 2013. Approved as a medication to treat major depressive disorder in adults, Levomilnacipran is designed as a once daily dose. As[…]

Read More

On May 29, 2013 the researchers from Duke Medicine revealed new findings about the benefits of the antidepressant Escitalopram CAS# 128196-01-0. Known as the brand name Lexapro, Escitalopram has long been touted as an efficacious and safe treatment for clinical depression. The latest findings regarding Escitalopram, reported in The Journal of the American Medical Association,[…]

Read More

The expiration for the patent of the new formulation of Prozac, also known as the generic drug Fluoxetine Hydrochloride, is slated for November 1, 2017. As a common and effectual antidepressant, Fluoxetine HCl CAS# 56296-78-7, has proven to be a valuable treatment for patients in the United States and worldwide. In fact, antidepressant use in[…]

Read More

Paroxetine Hydrochloride, known by the trade name Paxil, has an upcoming patent expiration date of May 19, 2015. As a well used medication to treat depression, Paroxetine HCl, CAS number 78246-49-8, is projected to become a generic powerhouse. Paroxetine is efficacious at treating not only major depression, but also obsessive compulsive disorder, panic disorder, social[…]

Read More

Duloxetine Hydrochloride CAS# 136434-34-9, is also known as the brand name Cymbalta marketed by Lilly. This effective antidepressant will be going off patent in June of 2013. Duloxetine hydrochloride is currently approved to treat the following: clinical depression; peripheral diabetic neuropathy pain, or nerve pain in the hands, feet, arms, and legs from diabetes; generalized[…]

Read More